IGFBP2 then activates the Insulin Growth Factor 1 receptor (IGF-1R) and downstream signaling of the anti-apoptotic protein AKT (or protein kinase B, PKB), thus promoting melanoma cell survival and drug resistance to MAPK signaling inhibitors [79]. Here, AKT1 is linked to melanoma.